Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment

Sponsor / Institution: Massachusetts General Hospital

Purpose

To learn more about whether taking Niagen, a daily supplement containing a form of vitamin B3, will improve cognitive function, mood, and daily activity in people with subjective cognitive decline (SCD) or mild cognitive impairment (MCI)

Study Design

Randomized block sequence, double-blind, placebo controlled

Dose

1200mg Niagen

Length of Intervention

8 week

Intrinsic Capacity

Cognition

Status

Not yet recruiting

Condition or Disease 

Cognition Disorders in Old Age

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Cognition, Not Yet RecruitingANAD Staff